Profound Medical Posts 43% Revenue Growth in Q4 2025, Expands Global Distribution
Event summary
- Q4 2025 revenue grew 43% year-over-year to $6.0 million, with full-year revenue reaching $16.1 million.
- TULSA-PRO installed base grew to 78 systems by year-end 2025, with expectations to reach 120 by end of 2026.
- Company secured $42.45 million in new financing in December 2025, strengthening its balance sheet.
- Strategic distribution agreements signed in Saudi Arabia, Australia, and New Zealand.
- Frank Baylis appointed to Board of Directors, replacing Kris Shah.
The big picture
Profound Medical's strong Q4 2025 results reflect accelerating adoption of its TULSA-PRO system, particularly in key academic centers like Johns Hopkins and Mount Sinai. The company's strategic distribution partnerships and recent financing position it for further global expansion, though it must navigate increasing competition in the interventional MRI space. The appointment of Frank Baylis to the Board brings valuable medical device industry experience that could be critical as Profound scales its operations.
What we're watching
- Revenue Growth
- Whether Profound Medical can sustain high double-digit to low triple-digit revenue growth as projected.
- Global Expansion
- The pace at which new distribution agreements will drive international revenue growth.
- Clinical Outcomes
- How the upcoming CAPTAIN trial results will impact market perception and adoption of TULSA-PRO.